Literature DB >> 28924284

Molecular biology of glioblastoma: Classification and mutational locations.

Shahid Hussain Soomro1, Li Rui Ting2, Yang Yi Qing1, Mingxin Ren1.   

Abstract

Glioblastomas are regarded as the most common malignant brain tumours with great morphological and genetical heterogeneity. They comprise 12% to 15% of all intracranial tumours, with its peak observed in the 8th decade of life. The five-year survival is only 5%. Primary glioblastomas are more common in elders while secondary glioblastomas mostly involve younger people. Based upon gene expression profile, researchers have classified glioblastomas into several subtypes. Genetic mutations provide an advanced standard platform essential for diagnosis, therapeutic remedies and prognosis of glioblastomas. Common mutations observed in glioblastomas are loss of heterozygosity at 10q followed by epidermal growth factor receptor amplification (34%) and others. Vascular occlusion model and tumour stem cell model can explain the possible mechanism in glioblastomas pathogenesis. This review highlights glioblastomas' classifications, genetic mutations, pathogenesis and prognosis of different sub-types.

Entities:  

Keywords:  Glioblastoma, Molecular classification, Genetic mutations, Pathogenesis, Prognosis.

Mesh:

Substances:

Year:  2017        PMID: 28924284

Source DB:  PubMed          Journal:  J Pak Med Assoc        ISSN: 0030-9982            Impact factor:   0.781


  17 in total

Review 1.  Depression and glioblastoma, complicated concomitant diseases: a systemic review of published literature.

Authors:  Luke Mugge; Tarek R Mansour; Megan Crippen; Yasaman Alam; Jason Schroeder
Journal:  Neurosurg Rev       Date:  2018-08-09       Impact factor: 3.042

Review 2.  MicroRNA-22: a Novel and Potent Biological Therapeutics in Neurological Disorders.

Authors:  Seyed Hamidreza Rastegar-Moghaddam; Alireza Ebrahimzadeh-Bideskan; Sara Shahba; Amir Mohammad Malvandi; Abbas Mohammadipour
Journal:  Mol Neurobiol       Date:  2022-02-14       Impact factor: 5.590

3.  MIR99AHG/miR-204-5p/TXNIP/Nrf2/ARE Signaling Pathway Decreases Glioblastoma Temozolomide Sensitivity.

Authors:  Liang Zhou; Junfeng Ma
Journal:  Neurotox Res       Date:  2022-07-29       Impact factor: 3.978

4.  Integrin α7: a major driver and therapeutic target for glioblastoma malignancy.

Authors:  Andreia M Nunes; Pamela Barraza-Flores; Christina R Smith; Dean J Burkin
Journal:  Stem Cell Investig       Date:  2017-12-18

Review 5.  Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment.

Authors:  Belén Delgado-Martín; Miguel Ángel Medina
Journal:  Adv Sci (Weinh)       Date:  2020-03-12       Impact factor: 16.806

6.  CD99 Expression in Glioblastoma Molecular Subtypes and Role in Migration and Invasion.

Authors:  Lais C Cardoso; Roseli da S Soares; Talita de S Laurentino; Antonio M Lerario; Suely K N Marie; Sueli Mieko Oba-Shinjo
Journal:  Int J Mol Sci       Date:  2019-03-06       Impact factor: 5.923

Review 7.  Deciphering the Role of Autophagy in Treatment of Resistance Mechanisms in Glioblastoma.

Authors:  Imran Khan; Mohammad Hassan Baig; Sadaf Mahfooz; Moniba Rahim; Busra Karacam; Elif Burce Elbasan; Ilya Ulasov; Jae-June Dong; Mustafa Aziz Hatiboglu
Journal:  Int J Mol Sci       Date:  2021-01-28       Impact factor: 5.923

8.  Radiomics Analysis Based on Magnetic Resonance Imaging for Preoperative Overall Survival Prediction in Isocitrate Dehydrogenase Wild-Type Glioblastoma.

Authors:  Shouchao Wang; Feng Xiao; Wenbo Sun; Chao Yang; Chao Ma; Yong Huang; Dan Xu; Lanqing Li; Jun Chen; Huan Li; Haibo Xu
Journal:  Front Neurosci       Date:  2022-01-28       Impact factor: 4.677

9.  Integrated Analysis of the Clinical and Molecular Characteristics of IDH Wild-Type Gliomas in the Chinese Glioma Genome Atlas.

Authors:  Peng Wang; Yanwei Liu; Lin Zhi; Xiaoguang Qiu
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

Review 10.  Neuroimmunomodulatory Properties of Flavonoids and Derivates: A Potential Action as Adjuvants for the Treatment of Glioblastoma.

Authors:  Ravena Pereira do Nascimento; Balbino Lino Dos Santos; Jéssika Alves Oliveira Amparo; Janaina Ribeiro Pereira Soares; Karina Costa da Silva; Monique Reis Santana; Áurea Maria Alves Nunes Almeida; Victor Diógenes Amaral da Silva; Maria de Fátima Dias Costa; Henning Ulrich; Vivaldo Moura-Neto; Giselle Pinto de Faria Lopes; Silvia Lima Costa
Journal:  Pharmaceutics       Date:  2022-01-04       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.